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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S389assuming that all joints were free of OA at 25 years of age. Second, we
examined the association between baseline BMI and incident hand OA
at follow-up (in joints free of hand OA at baseline). Analyses were
adjusted for age and sex and were performed by generalized estimating
equation (GEE) to account for within patient dependency. All analyses
were repeated using change in BMI as the predictor variable with
additional adjustment for BMI and follow-up time.
Results: Mean (SD) baseline BMI was 20.9 (2.2) kg/m2 at the age of 25
years, 25.6 (4.1) kg/m2 at the baseline examination, and 26.2 (3.7) kg/m2
at follow-up. At baseline, 566 (10.8%) joints had mild OA and 485 (9.2 %)
had moderate/severe OA. There was no signiﬁcant association between
BMI at 25 years of age and incident OA at the baseline examination
(Table), nor was there any association between BMI change from 25
years of age to baseline incident OA. In joints free of OA at the baseline
examination, 150 (6.2%) joints had incident mild OA and 118 (4.9%) had
incident moderate/severe OA at follow-up. There was no association
between baseline BMI or change in BMI between baseline and follow-up
(mean (SD) follow-up time 7.3 (0.6) years) and incident OA at follow-up
(Table). Similar strength of associations for mild and moderate/severe
OA indicates no association between BMI and rapid OA progression.
Conclusions: In the Oslo hand OA cohort, no association was observed
between self-reported BMI in early adulthood and later development of
hand OA. Similarly, we found no association between BMI and devel-
opment of hand OA in joints previously unaffected in patients with
established disease over a 7-year follow-up.Table: Associations between BMI and incident hand OA (analyses at joint level)
Incident hand OA (KLG¼2) or (95% CI) Incident hand OA (KLG¼3-4) or (95% CI)
Associations between BMI and incident hand OA at baseline (2001-03) *
BMI at 25 years of age 0.99 (0.92, 1.07) 1.09 (0.99, 1.20)
Change in BMI from 25 years to baseline 1.00 (0.96, 1.03) 1.01 (0.93, 1.08)
Associations between BMI and incident hand OA at follow-up (2008-09) **
BMI at baseline 1.02 (0.97, 1.06) 1.01 (0.93, 1.09)
Change in BMI from baseline to follow-up 0.95 (0.85, 1.06) 0.93 (0.81, 1.06)
*n¼5248 joints (from 176 patients) included in the analyses assuming no OA at the age of 25 years.
**n¼2494 joints (from 104 patients) with KLG 0-1 at baseline included in the analyses, 604 joints with KLG 2-4 were excluded. OR¼odds ratio, CI¼conﬁdence interval.691
PAIN, FUNCTION, QUALITY OF LIFE AND PHYSICAL ACTIVITY IN
TIBIOFEMORAL- AND PATELLOFEMORAL OSTEOARTHRITIS – A
CROSS-SECTIONAL POPULATIONBASED STUDY
F. Torstensson y, M. Andersson z, C. Thorstensson x. yDept. of
Orthopaedics, Skanes Univ. Hosp., Malm€o, Sweden; zRes. and Dev. Ctr.
Spenshult, Oskarstr€om, Sweden; x Sahlgrenska Academy, Gothenburg
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Purpose: Little is known about how osteoarthrtitis (OA) in the tibio-
femoraljoint (TF) and patellofemoraljoint (PF) differ in symptoms and
function. This cross-sectional study aimed to describe differences in
self-reported pain, symptoms, physical function, health related quality
of life (HRQL) and physical activity (PA) in persons with radiographic TF-
and/or PF OA or no radiographic OA.
Methods: 121 persons (45% women) from an ongoing populationbased
cohort study with chronic knee pain at inclusion (The Spenshult
cohort), mean age 64,5 years. 105 persons had radiographic examina-
tions and were included in the present study. Radiographic TF OA was
deﬁned as a joint spacewidth (JSW)< 3mm and PF OA< 5mm. Pain and
physical function were assessed using Knee injury and Osteoarthritis
Outcome Score (KOOS) and HRQL using EQ-5D. PA was estimated as
proportion of patients accumulating 150 activity minutes per week on
moderate intensity. Kruskal-Wallis test was used to compare groups for
pain, physical function, HRQL, age and Body Mass Index (BMI). Mann-
Whitney U-test was used for the post-hoc analysis (p-values <0,01).
Results: 49 persons (47%) had no OA according to JSW (no OA), 33 (31%)
had PF OA (PF), 16 (15%) had TF OA (TF) and 7 (7%) had both TF and PF OA
(TFþPF). There were signiﬁcant differences between groups in HRQL
(p¼0,009), KOOS pain (p¼0,023), KOOS symptoms (p¼0,017), KOOS
function in daily living (p¼0,029) and KOOS Sport/recreation (p¼0,002).
No signiﬁcant difference was found between groups in accumulating
150 activity minutes/week (proportion range from 57 to 90%, p¼0,13).TFþPF group reported signiﬁcant more pain, worse kneefunction and
worse HRQL.
Conclusions: PF OA is common. Persons with TFþPF OA reported worse
symptoms and HRQL. Further studies are needed to identify prognostic
factors for OA symptom development. Early preventive initiatives could
possibly prevent deterioration of symptoms.
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IN VITRO RELEASE OF CORTICOSTEROIDS IN A NEWMODEL OF SLOW
RELEASE PLATFORM IN THE TREATMENT OF OSTEOARTHRITIS.
S. Colen y, M. van Rijen z, S. Plomp z, L. Creemers z. yUniv. Hosp. Leuven,
Leuven, Belgium; zUniv. Med. Ctr. Utrecht, Utrecht, Netherlands
Abstract
Purpose: Corticosteroids (CS) are used for several treatments including
intra-articular treatment of osteoarthritis. However, these can have
severe side-effects, especially if patients have to be treated several times
in the same joint. Applying CS in a controlled releasemanner (CS applied
in microspheres (MS)), can possibly reduce the number of injections
with CS needed and also prevent side-effects. The aim of this in vitro
study is to show the efﬁcacy of MS loadedwith CS on humanTNF-alpha-
stimulated osteoarthritic (OA) chondrocytes in an in vitro model.
Methods: TNF-alpha stimulated OA chondrocytes from three human
donors were incubated in the presence of MS loaded with 5 wt% of
triamcinolone acetonide (TAA). MS were added to transwells atamounts estaimted to release in total 1x10-7 M TAA/3 days. Every three
days the cells and medium were collected and the transwells were
transferred to wells with freshly plated and stimulated OA chon-
drocytes. The total duration of the tests was 28 days. As controls we
used non-stimulated chondrocytes and TNF-alpha-stimulated OA
chondrocytes cultured in the presence of a bolus of 1x10-7 mol TAA and
empty (without TAA) MS. The bioactivity of the TA released from the
loaded MS was tested using PGE2 production as an outcome parameter
of inﬂammation (using PGE2 ELISA).
Results: Because of the large ﬂuctuation of the levels of PGE2 at the
different time points in the TNF-alpha-stimulated cells, all levels of
PGE2 determined in the treatment and control groups were divided by
the level of PGE2 in the TNF-alpha-stimulated cells (table 1). The PGE2-
level in the cells treated with a bolus of 1x10-7 mol TAA reached a
maximum of 4.6%. The highest percentage of PGE2 in the MS loaded
with 1x10-7 mol TAA/3 days group was 5.2% at time-point 8 (28 days
follow-up) (table 2). Although the levels of PGE2 in the empty MS and
non-TNF-alpha-stimulated cells compared to the negative control and
the levels of PGE2 in the empty MS and TNF-alpha-stimulated cells
compared to TNF-alpha-stimulated cells, seem to be higher at the ﬁrst
time point(s), this difference is never signiﬁcant. The levels of PGE2 in
the empty MS and non-TNF-alpha-stimulated cells compared to the
negative control and the levels of PGE2 in the emptyMS and TNF-alpha-
stimulated cells compared to TNF-alpha-stimulated cells showed no
signiﬁcant differences indicating that the MS are not causing any
additional inﬂammation (table 3 and 4).
Conclusions: This study showed that MS loaded with TAA signiﬁcantly
reduce inﬂammation in TNF-alpha induced OA chondrocytes over a
period of at least 28 days. The slow-release platform using MS loaded
with TAA in this study showed in vitro promising results for long term
inhibition of inﬂammation. In vivo studies (still in testing phase)
showed presence of intra-articular MS (using optical imaging) at least 8
weeks after intra-articular injection in a knee of a rat.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S390Table 1: PGE2-levels of all situations compared to PGE2-levels of chon-
drocytes treated with TNF-alpha
Table 2: PGE2-levels after TNF-alpha + TA -7 and MS -7 compared to
PGE2-levels after TNF-alpha
Table 3: PGE2-levels of negative control and no TNF-alpha and empty MS
compared to PGE2-levels of chondrocytes treated with TNF-alpha
Table 4: PGE2-levels of chondrocytes treated with TNF-alpha and MS
compared to PGE2-levels of chondrocytes treated with TNF-alpha693
CHARACTERIZATION OF OSTEOARTHRITIS PAIN VARIABILITY
R. Yeasted, J. McPherson, T. Schnitzer. Northwestern Univ., Chicago, IL,
USA
Purpose: Characterizing the temporal evolution of OA pain may be
critical for the development of more effective pain management
strategies. However, it remains largely unknown whether the char-
acteristics that deﬁne OA pain within the context of a clinical trial
also reﬂect the progression of OA pain outside of this framework
(i.e., during normal daily living). Therefore, this study seeks to
compare the dynamics of OA pain both within and outside of the
clinical trial setting. Speciﬁcally, we focus on two parameters of OA
pain that have signiﬁcant clinical implications: ﬂares of pain, and
the relationship between mean pain intensity and the variability of
pain over time.
Methods: Data were obtained from two longitudinal observational
studies and the placebo arms of two clinical trials. Eligibility criteria
for all studies were similar and included an age of at least 40 years,
knee OA pain for most days of the week on current pain treatment, a
minimum pain intensity of four or greater on the Numeric Rating
Scale (NRS) (0¼no pain, 10¼worst possible), and meeting the ACR
deﬁnition for knee OA. All participants were asked either to report
their pain on an electronic tablet two times a day (clinical trials) or on
their cellphones three times a day (observational studies) over a 12-16
week period. For statistical purposes, data from the two observational
studies were pooled to form a single cohort, and data from the two
clinical trial placebo arms were pooled to form a separate cohort.
Within each of the merged datasets we ﬁrst quantiﬁed the incidence,
prevalence, magnitude and length of pain ﬂares. Flare onset was
deﬁned as an average daily NRS score  4 and  9 with an increase of
at least two points over the mean pain score from the previous three
days; ﬂare offset was deﬁned as the ﬁrst time at which the average
daily NRS score no longer met or exceeded 2 NRS points above the
previous baseline. In addition to ﬂares, we also investigated the
strength and direction of a linear relationship between mean pain
intensity and variability in pain intensity across participants within
each group.
Results: Merger of the two observational studies resulted in a total of
65 participants, while merger of the two clinical trial arms resulted in
126 participants. The demographics of the two groups were similar
and typical of an OA population. In the combined observational group,
a total of 219 ﬂares were identiﬁed, with 87.3% of individuals having at
least one ﬂare during the study period. Of these participants, the
average number of ﬂares per month was 1.74 (95% CI: 1.44 - 2.05).
Average ﬂare magnitude was þ3.37 NRS points above baseline (95%
CI: 3.36 - 3.38) for this cohort, and ﬂares persisted for an average of
3.08 days (95% CI: 2.46 - 3.7). By comparison, 137 ﬂares were identi-
ﬁed in the merged clinical trial dataset, with only 24.6% of participants
having at least one ﬂare at an average rate of 0.82 (95% CI: 0.65 - 1.00)
ﬂares per month. Flare magnitude averaged þ2.62 NRS points above
baseline (95% CI: 2.61 - 2.63) in this group, and ﬂares persisted for an
average of 2.23 days (95% CI: 2.19 - 2.27). Mean ﬂare magnitude and
the number of ﬂares per month were signiﬁcantly greater for the
observational cohort (P << 0.01), while ﬂare length was not dis-
tinguishable between groups at the a ¼ 0.05 level. The relationship
between pain intensity and variability in reported pain was also
markedly different between study groups: whereas a positive linear
relationship was observed between increasing mean pain intensity
and increasing pain variability in the cohort of individuals in obser-
vational studies (Figure 1A), an inverse relationship was revealed
between mean pain intensity and variability in pain level within the
clinical trial cohort (Figure 1B).
Conclusions: This study reveals important distinctions between the
characteristics of OA pain within the context of observational studies
versus clinical trials, despite highly similar inclusion criteria. Further
research into the speciﬁc reasons for these differences will be essential
for the successful design, implementation and interpretation of future
trials.
